BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 31784510)

  • 1. A high-throughput screen identifies that CDK7 activates glucose consumption in lung cancer cells.
    Ghezzi C; Wong A; Chen BY; Ribalet B; Damoiseaux R; Clark PM
    Nat Commun; 2019 Nov; 10(1):5444. PubMed ID: 31784510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer.
    Wang J; Zhang R; Lin Z; Zhang S; Chen Y; Tang J; Hong J; Zhou X; Zong Y; Xu Y; Meng R; Xu S; Liu L; Zhang T; Yang K; Dong X; Wu G
    J Hematol Oncol; 2020 Jul; 13(1):99. PubMed ID: 32690037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDK7 inhibition as a promising therapeutic strategy for lung squamous cell carcinomas with a SOX2 amplification.
    Hur JY; Kim HR; Lee JY; Park S; Hwang JA; Kim WS; Yoon S; Choi CM; Rho JK; Lee JC
    Cell Oncol (Dordr); 2019 Aug; 42(4):449-458. PubMed ID: 30838525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression, and survival of tumor cells.
    Kelso TW; Baumgart K; Eickhoff J; Albert T; Antrecht C; Lemcke S; Klebl B; Meisterernst M
    Mol Cell Biol; 2014 Oct; 34(19):3675-88. PubMed ID: 25047832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer.
    Li B; Ni Chonghaile T; Fan Y; Madden SF; Klinger R; O'Connor AE; Walsh L; O'Hurley G; Mallya Udupi G; Joseph J; Tarrant F; Conroy E; Gaber A; Chin SF; Bardwell HA; Provenzano E; Crown J; Dubois T; Linn S; Jirstrom K; Caldas C; O'Connor DP; Gallagher WM
    Cancer Res; 2017 Jul; 77(14):3834-3845. PubMed ID: 28455421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. THZ1 targeting CDK7 suppresses c-KIT transcriptional activity in gastrointestinal stromal tumours.
    Sun J; Zhang Q; Sun X; Xue A; Gao X; Shen K
    Cell Commun Signal; 2022 Sep; 20(1):138. PubMed ID: 36076237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CDK7 inhibitor THZ1 alters RNA polymerase dynamics at the 5' and 3' ends of genes.
    Sampathi S; Acharya P; Zhao Y; Wang J; Stengel KR; Liu Q; Savona MR; Hiebert SW
    Nucleic Acids Res; 2019 May; 47(8):3921-3936. PubMed ID: 30805632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDK7 inhibition by THZ1 suppresses cancer stemness in both chemonaïve and chemoresistant urothelial carcinoma via the hedgehog signaling pathway.
    Chow PM; Chang YW; Kuo KL; Lin WC; Liu SH; Huang KH
    Cancer Lett; 2021 Jun; 507():70-79. PubMed ID: 33741425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of cyclin-dependent kinase 7 suppresses human hepatocellular carcinoma by inducing apoptosis.
    Zhong L; Yang S; Jia Y; Lei K
    J Cell Biochem; 2018 Dec; 119(12):9742-9751. PubMed ID: 30145799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. THZ1 suppresses human non-small-cell lung cancer cells in vitro through interference with cancer metabolism.
    Cheng ZJ; Miao DL; Su QY; Tang XL; Wang XL; Deng LB; Shi HD; Xin HB
    Acta Pharmacol Sin; 2019 Jun; 40(6):814-822. PubMed ID: 30446732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome.
    Wei Y; Li C; Bian H; Qian W; Jin K; Xu T; Guo X; Lu X; Su F
    Mol Cancer; 2021 Jan; 20(1):5. PubMed ID: 33397398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDK7 Inhibition is Effective in all the Subtypes of Breast Cancer: Determinants of Response and Synergy with EGFR Inhibition.
    McDermott MSJ; Sharko AC; Munie J; Kassler S; Melendez T; Lim CU; Broude EV
    Cells; 2020 Mar; 9(3):. PubMed ID: 32155786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. THZ1 Reveals Roles for Cdk7 in Co-transcriptional Capping and Pausing.
    Nilson KA; Guo J; Turek ME; Brogie JE; Delaney E; Luse DS; Price DH
    Mol Cell; 2015 Aug; 59(4):576-87. PubMed ID: 26257281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer.
    Lu P; Geng J; Zhang L; Wang Y; Niu N; Fang Y; Liu F; Shi J; Zhang ZG; Sun YW; Wang LW; Tang Y; Xue J
    Oncogene; 2019 May; 38(20):3932-3945. PubMed ID: 30692639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDK7 inhibitor THZ1 inhibits MCL1 synthesis and drives cholangiocarcinoma apoptosis in combination with BCL2/BCL-XL inhibitor ABT-263.
    Huang T; Ding X; Xu G; Chen G; Cao Y; Peng C; Shen S; Lv Y; Wang L; Zou X
    Cell Death Dis; 2019 Aug; 10(8):602. PubMed ID: 31399555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of the CDK7 Inhibitor on EMT-Associated Resistance to 3rd Generation EGFR-TKIs in Non-Small Cell Lung Cancer Cell Lines.
    Ji W; Choi YJ; Kang MH; Sung KJ; Kim DH; Jung S; Choi CM; Lee JC; Rho JK
    Cells; 2020 Dec; 9(12):. PubMed ID: 33287368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDK7 inhibition suppresses aberrant hedgehog pathway and overcomes resistance to smoothened antagonists.
    Liu F; Jiang W; Sui Y; Meng W; Hou L; Li T; Li M; Zhang L; Mo J; Wang J; Zhao Y; Zhang L; Ma J; Tang Y
    Proc Natl Acad Sci U S A; 2019 Jun; 116(26):12986-12995. PubMed ID: 31182587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma.
    Tee AE; Ciampa OC; Wong M; Fletcher JI; Kamili A; Chen J; Ho N; Sun Y; Carter DR; Cheung BB; Marshall GM; Liu PY; Liu T
    Int J Cancer; 2020 Oct; 147(7):1928-1938. PubMed ID: 32086952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanomaterial-Facilitated Cyclin-Dependent Kinase 7 Inhibition Suppresses Gallbladder Cancer Progression via Targeting Transcriptional Addiction.
    Huang CS; Xu QC; Dai C; Wang L; Tien YC; Li F; Su Q; Huang XT; Wu J; Zhao W; Yin XY
    ACS Nano; 2021 Sep; 15(9):14744-14755. PubMed ID: 34405985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Reduction of Glucose Consumption Is a Biomarker of Kinase Inhibitor Efficacy Which Can Be Reversed with GLUT1 Overexpression in Lung Cancer Cells.
    Ghezzi C; Perez S; Ryan K; Wong A; Chen BY; Damoiseaux R; Clark PM
    Mol Imaging Biol; 2023 Jun; 25(3):541-553. PubMed ID: 36284040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.